11.83
-0.35(-2.87%)
Currency In USD
| Previous Close | 12.18 |
| Open | 12.15 |
| Day High | 12.17 |
| Day Low | 11.71 |
| 52-Week High | 12.68 |
| 52-Week Low | 6.69 |
| Volume | 1.2M |
| Average Volume | 1.72M |
| Market Cap | 3.72B |
| PE | 1,182.5 |
| EPS | 0.01 |
| Moving Average 50 Days | 10.89 |
| Moving Average 200 Days | 8.93 |
| Change | -0.35 |
If you invested $1000 in Amneal Pharmaceuticals, Inc. (AMRX) since IPO date, it would be worth $799.13 as of December 04, 2025 at a share price of $11.995. Whereas If you bought $1000 worth of Amneal Pharmaceuticals, Inc. (AMRX) shares 5 years ago, it would be worth $2,849.17 as of December 04, 2025 at a share price of $11.995.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Amneal Receives U.S. FDA Approval for Albuterol Sulfate Inhalation Aerosol
GlobeNewswire Inc.
Dec 02, 2025 1:00 PM GMT
Represents second complex respiratory therapeutic product approval in Q4 2025BRIDGEWATER, N.J., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (Nasdaq: AMRX) today announced that the U.S. Food and Drug Ad
Amneal to Participate in Upcoming Investor Conferences
GlobeNewswire Inc.
Dec 02, 2025 1:00 PM GMT
BRIDGEWATER, N.J., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) today announced that Chirag Patel, Co-Chief Executive and President, and Tasos Konidaris, Chief Financial Officer, will participate in following upcomi
Amneal Announces U.S. FDA Approval of Cyclosporine Ophthalmic Emulsion 0.05%
GlobeNewswire Inc.
Dec 01, 2025 9:01 PM GMT
Approval underscores Amneal’s advanced sterile manufacturing capabilities and expansion within complex ophthalmic therapies; Launch expected in Q1 2026 BRIDGEWATER, N.J., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or